MediWound (NASDAQ: MDWD) and USANA Health Sciences (NYSE:USNA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, dividends, valuation and profitability.
Valuation and Earnings
This table compares MediWound and USANA Health Sciences’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|MediWound||$2.50 million||54.64||-$22.14 million||($0.62)||-8.15|
|USANA Health Sciences||$1.05 billion||2.20||$62.53 million||$4.06||23.58|
Institutional and Insider Ownership
32.9% of MediWound shares are owned by institutional investors. Comparatively, 49.5% of USANA Health Sciences shares are owned by institutional investors. 48.0% of USANA Health Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk and Volatility
MediWound has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500. Comparatively, USANA Health Sciences has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.
This is a breakdown of current ratings for MediWound and USANA Health Sciences, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|USANA Health Sciences||0||2||0||0||2.00|
MediWound presently has a consensus target price of $9.83, suggesting a potential upside of 94.72%. USANA Health Sciences has a consensus target price of $95.00, suggesting a potential downside of 0.78%. Given MediWound’s stronger consensus rating and higher probable upside, analysts clearly believe MediWound is more favorable than USANA Health Sciences.
This table compares MediWound and USANA Health Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|USANA Health Sciences||5.97%||27.08%||19.75%|
USANA Health Sciences beats MediWound on 10 of the 14 factors compared between the two stocks.
MediWound Company Profile
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition. It also provides Sensé?beautiful science products, such as personal care products that support healthy skin and hair through topical nourishment, moisturization, and protection; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.